Clinical trials data
Trail Making Test in cancer trials: 187 registered studies
Every registered cancer study on ClinicalTrials.gov that names the Trail Making Test in an outcome measure: how often it is a primary outcome, the tests named with it, how large the studies are and when they measure it.
- Registered cancer studies name it in an outcome measure
- 187
- Name it in a primary outcome, 29%
- 54 of 187
Tests named in the same studies
- 1
Verbal Learning121 studies, 46 as a primary outcome
- 2
Verbal Fluency119 studies, 37 as a primary outcome
- 3
Digit Span Test52 studies, 20 as a primary outcome
- 4
Symbol Coding27 studies, 14 as a primary outcome
- 5
Stroop Color-Word Test26 studies, 9 as a primary outcome
- 6
Category Fluency15 studies, 4 as a primary outcome
- 7
Task Switching Test10 studies, 2 as a primary outcome
- 8
Paced Visual Serial Addition Test9 studies, 5 as a primary outcome
- 9
Picture Naming Test9 studies, 5 as a primary outcome
- 10
Continuous Performance Test8 studies, 4 as a primary outcome
A test as a primary outcomeOnly in secondary or other outcomes
Studies by start year
A test as a primary outcomeOnly in secondary or other outcomes
Show as a table
| Start year | Studies | A test as a primary outcome |
|---|---|---|
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 1 | 0 |
| 2003 | 1 | 1 |
| 2004 | 2 | 1 |
| 2005 | 1 | 1 |
| 2006 | 1 | 0 |
| 2007 | 1 | 0 |
| 2008 | 2 | 0 |
| 2009 | 4 | 0 |
| 2010 | 1 | 1 |
| 2011 | 4 | 0 |
| 2012 | 2 | 0 |
| 2013 | 3 | 1 |
| 2014 | 7 | 3 |
| 2015 | 10 | 5 |
| 2016 | 9 | 0 |
| 2017 | 16 | 3 |
| 2018 | 11 | 4 |
| 2019 | 10 | 5 |
| 2020 | 12 | 5 |
| 2021 | 16 | 6 |
| 2022 | 10 | 3 |
| 2023 | 13 | 3 |
| 2024 | 15 | 4 |
| 2025 | 12 | 0 |
| 2026 | 22 | 8 |
Phases and study sizes
By phase
- Early phase 11 studies, 0 as a primary outcome
- Phase 11 studies, 0 as a primary outcome
- Phase 1/25 studies, 1 as a primary outcome
- Phase 231 studies, 5 as a primary outcome
- Phase 2/31 studies, 0 as a primary outcome
- Phase 318 studies, 5 as a primary outcome
- Phase 42 studies, 0 as a primary outcome
- Not applicable83 studies, 22 as a primary outcome
- Observational45 studies, 21 as a primary outcome
Participants per study
- Phase 269 median, 43 to 98
- Phase 3318 median, 187 to 501
- Not applicable70 median, 40 to 114
- Observational100 median, 40 to 148
Show as a table
| Phase | Studies with a size | Median | Middle half |
|---|---|---|---|
| Phase 2 | 30 | 69 | 43 to 98 |
| Phase 3 | 18 | 318 | 187 to 501 |
| Not applicable | 80 | 70 | 40 to 114 |
| Observational | 45 | 100 | 40 to 148 |
When cancer trials measure it
Latest time point of each outcome
- Within a day15 outcomes, 4 as a primary outcome
- Up to 4 weeks9 outcomes, 1 as a primary outcome
- 1 to 3 months35 outcomes, 11 as a primary outcome
- 3 to 6 months36 outcomes, 11 as a primary outcome
- 6 to 12 months48 outcomes, 15 as a primary outcome
- 1 to 2 years21 outcomes, 6 as a primary outcome
- Over 2 years18 outcomes, 3 as a primary outcome
- No duration given5 outcomes, 3 as a primary outcome
A test as a primary outcomeOnly in secondary or other outcomes
182 of the 187 outcome measures give a duration. A single visit counts as within a day.
Status, results, interventions and countries
Status
- Recruiting50 studies, 15 as a primary outcome
- Not yet recruiting9 studies, 4 as a primary outcome
- Active, not recruiting23 studies, 3 as a primary outcome
- Completed64 studies, 21 as a primary outcome
- Stopped early14 studies, 3 as a primary outcome
- Status unknown27 studies, 8 as a primary outcome
What they test
- Behavioral40 studies, 13 as a primary outcome
- Drug52 studies, 10 as a primary outcome
- Device17 studies, 4 as a primary outcome
- Procedure11 studies, 4 as a primary outcome
- Diagnostic test8 studies, 2 as a primary outcome
- Biological5 studies, 0 as a primary outcome
- Radiation53 studies, 14 as a primary outcome
- Other51 studies, 13 as a primary outcome
- None given17 studies, 10 as a primary outcome
Intervention types as registered. A study can list several; observational studies often list none.
Where their sites are
- United States87 studies, 28 as a primary outcome
- Canada22 studies, 5 as a primary outcome
- France17 studies, 2 as a primary outcome
- Spain13 studies, 3 as a primary outcome
- Italy11 studies, 4 as a primary outcome
- Germany10 studies, 0 as a primary outcome
- Netherlands10 studies, 2 as a primary outcome
- China8 studies, 1 as a primary outcome
- Denmark6 studies, 2 as a primary outcome
- Australia5 studies, 0 as a primary outcome
- United Kingdom5 studies, 0 as a primary outcome
- Austria4 studies, 0 as a primary outcome
32 countries in all. A study with sites in several counts in each; 5 list no site.
Reported results
Completed studies with results posted on ClinicalTrials.gov, a results paper the registry links to the study, or both.
Completed cancer studies that name the Trail Making Test: 36 of 64, 56%
Every completed study with a cognitive outcome: 3,626 of 7,953, 46%
| Results | Completed cancer studies that name the Trail Making Test | Every completed study |
|---|---|---|
| Results on ClinicalTrials.gov and a paper | 11, 17% | 776, 10% |
| Results on ClinicalTrials.gov only | 9, 14% | 1,139, 14% |
| A results paper only | 16, 25% | 1,711, 22% |
| Neither | 28, 44% | 4,327, 54% |
The 187 studies
187 studies match. 54 name the Trail Making Test in a primary outcome. Median size 86 participants. Median time to the primary outcome: 6 months.
Loading 187 studies; the filters turn on when they arrive.
2026 is partly planned starts. Not shown: 1 planned to start after 2026.
Show as a table
| Start year | Studies | As a primary outcome |
|---|---|---|
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 1 | 0 |
| 2003 | 1 | 1 |
| 2004 | 2 | 1 |
| 2005 | 1 | 1 |
| 2006 | 1 | 0 |
| 2007 | 1 | 0 |
| 2008 | 2 | 0 |
| 2009 | 4 | 0 |
| 2010 | 1 | 1 |
| 2011 | 4 | 0 |
| 2012 | 2 | 0 |
| 2013 | 3 | 1 |
| 2014 | 7 | 3 |
| 2015 | 10 | 5 |
| 2016 | 9 | 0 |
| 2017 | 16 | 3 |
| 2018 | 11 | 4 |
| 2019 | 10 | 5 |
| 2020 | 12 | 5 |
| 2021 | 16 | 6 |
| 2022 | 10 | 3 |
| 2023 | 13 | 3 |
| 2024 | 15 | 4 |
| 2025 | 12 | 0 |
| 2026 | 22 | 8 |
Library tests named most
Largest condition groups
Phases
Participants
Lead sponsor: industry 10, NIH 1, other 176. Interventional 142, observational 45.
As a primary outcomeSecondary or other outcomeThe Trail Making Test
The studies, newest registration first
Each number opens the study's record on ClinicalTrials.gov.
| Study | Start | Phase | Conditions | Participants | Lead sponsor | Status | Library tests named, with the latest time point |
|---|---|---|---|---|---|---|---|
| NCT07908147 | Start2027 | PhaseEarly phase 1 | ConditionsCancer | Participants12 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07867886 | Start2026 | PhaseNot applicable | ConditionsCancer | Participants30 | Lead sponsorIndustry | StatusNot yet recruiting | Library tests named
|
| NCT07755839 | Start2026 | PhaseNot applicable | ConditionsDepression and bipolar disorder, Cancer, Anxiety, PTSD and OCD | Participants60 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07740317 | Start2026 | PhaseObservational | ConditionsCancer | Participants50 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07729969 | Start2026 | PhaseNot applicable | ConditionsCancer | Participants110 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07716800 | Start2026 | PhaseObservational | ConditionsCancer, Delirium, surgery and intensive care | Participants205 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07710131 | Start2026 | PhaseNot applicable | ConditionsCancer | Participants36 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07652476 | Start2026 | PhaseObservational | ConditionsCancer | Participants100 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07638852 | Start2026 | PhasePhase 2 | ConditionsCancer | Participants58 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07633626 | Start2026 | PhaseObservational | ConditionsDepression and bipolar disorder, Cancer | Participants24 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07587957 | Start2026 | PhaseNot applicable | ConditionsCancer | Participants40 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07470606 | Start2026 | PhasePhase 2 | ConditionsCancer | Participants108 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07463781 | Start2026 | PhaseObservational | ConditionsCancer | Participants100 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07452458 | Start2026 | PhasePhase 3 | ConditionsCancer | Participants398 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07390045 | Start2026 | PhaseNot applicable | ConditionsCancer | Participants40 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07383649 | Start2026 | PhasePhase 2 | ConditionsCancer | Participants28 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07357636 | Start2019 | PhaseObservational | ConditionsCancer | Participants940 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07292272 | Start2026 | PhaseNot applicable | ConditionsCancer | Participants180 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07259434 | Start2026 | PhaseNot applicable | ConditionsCancer, Cardiovascular disease | Participants152 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07248228 | Start2026 | PhasePhase 2 | ConditionsCancer | Participants90 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07173101 | Start2025 | PhasePhase 2 | ConditionsCancer | Participants7 | Lead sponsorOther | StatusStopped early | Library tests named
|
| NCT07160751 | Start2026 | PhaseObservational | ConditionsCancer | Participants90 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07159854 | Start2025 | PhaseNot applicable | ConditionsCancer | Participants60 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07132190 | Start2025 | PhasePhase 2 | ConditionsCancer | Participants60 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07125209 | Start2026 | PhaseObservational | ConditionsCancer | Participants18 | Lead sponsorOther | StatusRecruiting | Library tests named
|
Questions, answered from the data
How many cancer trials use the Trail Making Test?
187 registered cancer studies on ClinicalTrials.gov name it in an outcome measure, 54 of them in a primary outcome: 25% of the condition's 760 studies with a cognitive outcome, against 14% of all of them. It is the 3rd most named test in cancer trials.
Which tests do cancer trials use with the Trail Making Test?
Verbal Learning (121 studies), Verbal Fluency (119 studies) and the Digit Span Test (52 studies).
How many participants do phase 2 cancer trials that use the Trail Making Test enroll?
Half of the phase 2 studies that name it enroll 69 participants or fewer, and the middle half enroll 43 to 98. 30 of them give a size.
When do cancer trials measure the Trail Making Test?
Half of the primary outcomes that name the Trail Making Test are measured within 6 months of the start, and the middle half from 12 weeks to 12 months. 51 primary outcomes give a duration.
How many completed cancer trials that use the Trail Making Test have reported results?
36 of the 64 completed studies that name it, 56%, have reported results: 20 posted them on ClinicalTrials.gov, 27 have a results paper linked to the registry record, and 11 did both. The other 28 show neither. Of all completed studies with a cognitive outcome, 46% have reported results.
How the studies are counted
For each test family, the census runs ClinicalTrials.gov's own outcome search for the family's names and reads every study first posted by the day the family was counted. These studies were read on 10 November 2026. A study counts once on a page, however many tests it names. Counts for a test cover every version of the task under any of its names, so a page can count studies that used a commercial version.
The census adds two things to each record and changes nothing in it: which outcome list names the test (primary, then secondary, then other), and the condition groups, matched on the study's condition names and MeSH terms. A study can fall in several groups; one whose only condition is cognitive impairment or decline falls in “Cognitive impairment and decline”. Studies that name only instruments outside the library count in every total and share but are not listed.
A second read on 10 November 2026 added each study's overall status, whether results are posted, its intervention types, the countries of its sites and the time frame of the outcome that names each test. A time frame counts by the latest time point it names: “Baseline, 12 and 24 weeks” is 24 weeks, a single visit is within a day, and one that names no duration, such as “end of treatment”, is left out of the timings.
A third read on 10 November 2026 added the papers the registry links to each study: those its sponsor lists as reporting results, and those PubMed links to it through the study's NCT number. A study has a results paper when one of them came out in or after the month of its primary completion and PubMed does not class it as a protocol, review or comment. A paper that never gives the NCT number is not linked, so some studies counted as reporting neither did publish.
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine, which does not endorse these pages. Every study line is in the data release 2.1.0, and the explorer's own file is clinical-trials-studies.json.
The census counts Trail Making Test A and Trail Making Test B as one test family, so this page counts their studies together.
Run the Trail Making Test in your trial
Choose tests with a record in registered trials, and run them in a browser at every site, on the same version each visit.